替吉奥联合顺铂治疗晚期胃癌的疗效观察

Therapeutic efficacy of tegafur combined with cisplatin in the treatment of advanced gastric cancer

目的探讨替吉奥联合顺铂治疗晚期胃癌的疗效。方法选取2015年3月至2018年1月间陕西省渭南市潼关县人民医院收治的84例晚期胃癌患者,采用随机数表法分为研究组和对照组,每组42例,研究组患者采用替吉奥联合顺铂治疗,对照组患者采用5-氟尿嘧啶联合顺铂治疗,采用实体瘤疗效评价标准进行疗效评估,比较两组治疗结果。结果研究组患者的总有效率为78. 6%,明显高于对照组患者的64. 3%,差异有统计学意义(P <0. 05)。研究组患者的不良反应发生率为11. 9%,明显低于对照组患者的26. 2%,差异有统计学意义(P <0. 05)。结论替吉奥联合顺铂治疗晚期胃癌的效果明显,可减少不良反应产生率,安全性高,促进病情快速稳定。

Objective To study the efficacy of tegafur plus cisplatin in the treatment of advanced gastric cancer.Methods A total of 84 patients with advanced gastric cancer admitted to Tongguan County People’s Hospital from March 2015 to January 2018 were selected and randomly divided into a study group and a control group according to the digital table method with 42 patients in each group.The study group was treated with tegafur plus cisplatin,and the control group was treated with 5-fluorouracil plus cisplatin.The treatment efficacy was evaluated by response evaluation criteria in solid tumors(RECIST),and the therapeutic results were compared between the two groups.Results The overall effective rate was 78.6%in the study group which was higher than that 64.3%in the control group(P<0.05).The incidence of adverse reactions was 11.9%in the study group which was significantly lower than 26.2%of the control group(P<0.05).Conclusion Tegafur plus cisplatin has obvious efficacy for advanced gastric cancer,which reduces adverse reactions and promotes the stability of the disease with good safety.